Epic Systems Corporation appears in FDA device records as the applicant for a single documented submission, K260008, received January 2, 2026 and decided September 18, 2026. The filing covers Deterioration Index Version 2, a software device assigned to the cardiovascular advisory committee and cleared through the Traditional 510(k) pathway with a Summary statement. The supplied collection holds one linked record, all of it under the 510(k) pathway, with a decision count of one Substantially Equivalent outcome; that count describes the supplied filings as of the snapshot date, not company sales, total portfolio or safety performance. [1][9]
The documented device and its regulatory identity
Deterioration Index Version 2 is listed under trade name in the September 18, 2026 clearance letter, with regulation number 21 CFR 870.2210, regulation name Adjunctive Predictive Cardiovascular Indicator, Class II, product code QNL. The FDA record gives the applicant as Epic Systems Corporation at 1979 Milky Way, Verona, Wisconsin, and names Brian Jacobson as contact; the letter addresses Melissa Knox as official correspondent at the same address. A filing address is not evidence of a headquarters location. [1][2]
The 510(k) summary describes the device as drawing on Epic EHR data, such as vitals documented for the patient, and concludes that differences from the predicate do not raise new or different questions of safety or effectiveness. The predicate is identified in the summary as the device cleared under K233253. [2]
Submission dates and review details
The FDA record shows date received January 2, 2026, decision date September 18, 2026, decision code SESE with description Substantially Equivalent, clearance type Traditional, third-party flag N, and statement or summary listed as Summary. The clearance letter carries a later dated and received pair, August 20 and August 21, 2026, alongside the same K number and regulation details. [1][2]
A third-party index of the same filing repeats the K260008 identifiers, the QNL product code, the cardiovascular review panel, Class II classification and the Substantially Equivalent decision dated 2026-09-18. That index also lists other QNL-coded records from different applicants, which are separate filings and not part of this company's documented submission. [9]
Distribution record and published material
A GUDID-derived record lists Deterioration Index Version 2 under primary DI 00850053416019, company EPIC SYSTEMS CORPORATION, model 2, published 2026-10-26, with public version status New and distribution status In Commercial Distribution. The same record marks Rx, OTC, sterile and single-use fields false and states that labeling does not contain MRI safety information. [8]
EpicShare, published by Epic Systems Corporation, carries case-study material on the Deterioration Index predictive model, including accounts from named health systems about mortality changes and workflow effects after adoption. Those figures are the publisher's reported experiences, not findings established by the FDA filing, and they describe the model family rather than the specific cleared version. [5][7]
A JAMA Network Open article by Byrd and colleagues is titled as a validation of a proprietary deterioration index model and performance in hospitalized adults, and its reference list cites EpicShare material and earlier published work on an electronic medical record-based alert score. The public information does not report the validation results. [6]
What the record does and does not establish
The public information supports a narrow statement: one Traditional 510(k), K260008, cleared as substantially equivalent for Deterioration Index Version 2, with a summary on file and a GUDID entry indicating commercial distribution. No parent company, brand ownership, customer list, certification or independent performance result is verified in these sources. [1][8]
The collection counts are an as-of snapshot of the supplied filings: one linked record, one 510(k) pathway entry, one SESE decision, and a record sample containing the same single entry. They are not a measure of total company portfolio, market position or safety performance, and no recall sample is present in the public information. [1][9]

